Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Current Deferred Revenue: 2020-2025

Historic Current Deferred Revenue for iSpecimen (ISPC) over the last 5 years, with Sep 2025 value amounting to $155,506.

  • iSpecimen's Current Deferred Revenue fell 45.16% to $155,506 in Q3 2025 from the same period last year, while for Sep 2025 it was $155,506, marking a year-over-year decrease of 45.16%. This contributed to the annual value of $360,708 for FY2024, which is 13.24% down from last year.
  • Per iSpecimen's latest filing, its Current Deferred Revenue stood at $155,506 for Q3 2025, which was down 5.22% from $164,066 recorded in Q2 2025.
  • In the past 5 years, iSpecimen's Current Deferred Revenue ranged from a high of $802,860 in Q2 2021 and a low of $46,910 during Q3 2023.
  • Its 3-year average for Current Deferred Revenue is $219,595, with a median of $258,872 in 2024.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 82.79% in 2023, then soared by 504.50% in 2024.
  • iSpecimen's Current Deferred Revenue (Quarterly) stood at $654,746 in 2021, then slumped by 79.79% to $132,335 in 2022, then soared by 214.18% to $415,771 in 2023, then dropped by 13.24% to $360,708 in 2024, then plummeted by 45.16% to $155,506 in 2025.
  • Its Current Deferred Revenue stands at $155,506 for Q3 2025, versus $164,066 for Q2 2025 and $270,208 for Q1 2025.